- Home
- EYEN vs IKNA Comparison
EYEN vs IKNA Comparison
Compare EYEN & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- IKNA
- Stock Information
- Founded
- EYEN 2014
- IKNA 2016
- Country
- EYEN United States
- IKNA United States
- Employees
- EYEN N/A
- IKNA N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- IKNA Health Care
- Exchange
- EYEN Nasdaq
- IKNA Nasdaq
- Market Cap
- EYEN 38.2M
- IKNA 83.0M
- IPO Year
- EYEN 2018
- IKNA 2021
- Fundamental
- Price
- EYEN $0.55
- IKNA $1.68
- Analyst Decision
- EYEN Strong Buy
- IKNA Buy
- Analyst Count
- EYEN 2
- IKNA 2
- Target Price
- EYEN $12.00
- IKNA $3.00
- AVG Volume (30 Days)
- EYEN 879.0K
- IKNA 41.6K
- Earning Date
- EYEN 11-11-2024
- IKNA 11-07-2024
- Dividend Yield
- EYEN N/A
- IKNA N/A
- EPS Growth
- EYEN N/A
- IKNA N/A
- EPS
- EYEN N/A
- IKNA N/A
- Revenue
- EYEN $31,405.00
- IKNA $1,844,000.00
- Revenue This Year
- EYEN $50,309.30
- IKNA N/A
- Revenue Next Year
- EYEN $421.63
- IKNA N/A
- P/E Ratio
- EYEN N/A
- IKNA N/A
- Revenue Growth
- EYEN N/A
- IKNA N/A
- 52 Week Low
- EYEN $0.37
- IKNA $1.02
- 52 Week High
- EYEN $2.57
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- EYEN 52.60
- IKNA 51.57
- Support Level
- EYEN $0.52
- IKNA $1.68
- Resistance Level
- EYEN $0.59
- IKNA $1.78
- Average True Range (ATR)
- EYEN 0.05
- IKNA 0.04
- MACD
- EYEN 0.01
- IKNA 0.00
- Stochastic Oscillator
- EYEN 66.45
- IKNA 36.36
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.